Drugs / CVI-VZV-001
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06137755 | Mar 2023 → Mar 2025 overdue | herpes zoster | CHA Vaccine Institute Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07481604 | Apr 2026 → Jan 2027 expected | herpes zoster | CHA Vaccine Institute Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVI-VZV-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07481604 ↗ |
| Modality | Vaccine | “Recombinant Herpes Zoster Vaccine(CVI-VZV-001) 0.37 mL per dose” NCT06137755 ↗ |
| Route | Intramuscular | “Intramuscular injection at Baseline, Week 8 / total 2 doses” NCT06137755 ↗ |